Moffitt Cancer Center
Moffitt Cancer Center is at the very forefront of cancer centers worldwide in pioneering advances like CAR T-cell therapy, a promising approach to immunotherapy that uses a patient’s own immune cells to recognize and attack their tumors.
Moffitt Cancer Center’s Malignant Hematology Program, one of the largest Myelodysplastic Syndromes (MDS) programs in the nation, provides comprehensive, multispecialty treatment for patients with all forms of MDS and acute myeloid leukemia (AML). They understand that each patient responds differently to therapy, so their experienced team of oncologists, hematologists, medical oncologists, supportive care providers and other team members thoroughly assess each patient’s case to determine the most appropriate options for working toward remission and bringing blood cell counts as close to normal as possible. A patient’s individualized recommendation might include a combination of the following MDS therapies:
• Chemotherapy
• Immunotherapy
• Targeted therapy
• Stem cell and bone marrow transplants
At Moffitt, all MDS therapies are provided in a single location, making it easier for patients to access the outstanding treatments they deserve without the stress of traveling from clinic to clinic.
